NCT06735222View on ClinicalTrials.gov

Bioavailability of Hydroxytyrosol in Humans Co-administered With EPA

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions
HealthyYoung
Interventions
DIETARY_SUPPLEMENT

Hydroxytyrosol acetate (HT-Ac)

Hydroxytyrosol acetate (15 mg) orally co-administered with 2 g EPA

DIETARY_SUPPLEMENT

Hydroxytyrosol eicosapentanoate (HT-EPA)

Oral intake of hydroxytyrosol eicosapentanoate (15 mg) solubilized in an EPA-enriched oil matrix.

DIETARY_SUPPLEMENT

Oleacore®

Oleacore® (containing 15 mg of hydroxytyrosol) orally co-administered with 2 g EPA

Trial Locations (1)

28040

Ictan-Csic, Madrid

Sponsors
All Listed Sponsors
collaborator

Olivenova Health Sl

UNKNOWN

lead

National Research Council, Spain

OTHER_GOV